Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 2Phase NA 1Phase 2/3 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 1

Conditions

Breast Neoplasms 1129Carcinoma, Non-Small-Cell Lung 718Neoplasms 546Prostatic Neoplasms 505Colorectal Neoplasms 439Multiple Myeloma 338Lung Neoplasms 310Neoplasm Metastasis 289Leukemia, Myeloid, Acute 263Stomach Neoplasms 248Carcinoma, Hepatocellular 246Ovarian Neoplasms 225Rectal Neoplasms 211Colonic Neoplasms 204Lymphoma, Follicular 200Lymphoma 199Leukemia 190Uterine Cervical Neoplasms 181Head and Neck Neoplasms 174Pancreatic Neoplasms 172Lymphoma, Non-Hodgkin 167Leukemia, Lymphocytic, Chronic, B-Cell 166Lymphoma, Large B-Cell, Diffuse 163Recurrence 162Melanoma 158Precursor Cell Lymphoblastic Leukemia-Lymphoma 154Squamous Cell Carcinoma of Head and Neck 147Pain 141Urinary Bladder Neoplasms 139Brain Neoplasms 133

Interventions

luspatercept 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × beta-Thalassemia × Clear all
NCT04064060 2026-05-28

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Celgene

Phase 3 Recruiting
665 enrolled
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia

NCT02604433 2023-04-18

BELIEVE

Celgene

Phase 3 Completed
336 enrolled 38 charts 1 FDA

beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡